Inspirna snags $50M in funding

Inspirna has raised $50 million in a series D financing round primarily led by Sands Capital and Vivo Capital.

Advertisement

Inspirna is a biopharmaceutical company. Proceeds from the financing will go toward the development of the company’s small molecule inhibitor drugs RGX-202, designed to treat colorectal cancer, and RGX-104, designed to treat lung and endometrial cancer, according to a July 11 press release.

Michael Ginder of Sands Capital and Jack Nielsen of Vivo Capital are set to join Inspirna’s board of directors.

Advertisement

Next Up in Health IT

Advertisement

Comments are closed.